| International Session（Panel Discussion）1(JSH・JSGE・JSGCS) |
| Fri. November 6th 9:40 - 12:00 Room 8: Portopia Hotel Main Building Kairaku 1+2 |
| Similar HCC risk with TDF and ETV in chronic hepatitis B: A systematic review and meta-analysis | |||
| Masaru Enomoto1, Tetsuya Hosaka2, Mindie Nguyen3 | |||
| 1Department of Hepatology, Osaka City University, 2Department of Hepatology, Toranomon Hospital, 3GI & Hepatology, Stanford University | |||
|
|||
|
|||
| Background: Prior studies have reported lower HCC risk with TDF vs. ETV, but this can be due to background risk differences. We aimed to systematically review and meta-analyze HCC incidence in ETV and TDF for unmatched and matched data and for relevant subgroups. Methods: We searched PubMed, Cochrane Library, EMBASE, and Web of Science up to 3/22/2020 for relevant studies. We used random effects model to estimate pooled HCC incidence. Results: We screened 4,375 studies and analyzed 34 studies (119,673 participants). Overall, the 5-year HCC incidence was 6.14% (95% CI, 5.98-6.30%) for ETV and 3.10% (95% CI, 2.91-3.30%) for TDF from studies with unmatched data; 3.34% (95% CI, 2.99-3.70%) for ETV and 3.39% (95% CI, 2.94-3.83%) for TDF from studies with matched data. TDF was not significantly associated with lower HCC risk compared to ETV in 14 comparative studies with matched data or adjusted analyses (aHR 0.86, 95% CI 0.70-1.1, p=0.13). There was significant heterogeneity (I2 = 55.7%, p=0.006); and in subgroup analysis, TDF was significantly associated with lower HCC risk in studies using administrative databases (aHR 0.65; 95% CI 0.50-0.84) but not in studies using clinical cohort data (aHR 0.96, 95% CI 0.80-1.14). Conclusion: HCC risk was similar with ETV and TDF in data from well-matched clinical cohort studies. |
|||
|
Index Term 1: tenofovir Index Term 2: entecavir |
|||
| Page Top | |||